This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
by Zacks Equity Research
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Charles River (CRL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Growth Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 2nd
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
US Economy Had a Banner 2018: Top 5 Gainers
by Tirthankar Chakraborty
The U.S. GDP grew 2.9% in 2018, matching 2015 as the biggest increase since the 2007-2009 Great Recession.
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
4 Drug Stocks to Buy Despite Price Hearing Woes
by Nitish Marwah
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
Charles River (CRL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 7.19% and 1.94%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Charles River Laboratories (CRL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYNH vs. CRL: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. CRL: Which Stock Is the Better Value Option?
Charles River Laboratories (CRL) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 10.87% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 10.96% and 2.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.
Here's Why Teladoc Reaches a 52 Week High, Stock Up 22%
by Zacks Equity Research
Teladoc's (TDOC) robust results and a favorable guidance increase the stock price.
Should You Buy Charles River Laboratories (CRL) Before Earnings?
by Zacks Equity Research
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
by Zacks Equity Research
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Why Earnings Season Could Be Great for Charles River Laboratories (CRL)
by Zacks Equity Research
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR
by Zacks Equity Research
Let's see what awaits these three medical services stocks that are slated to release their first-quarter 2017 results on May 10.
Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q
by Zacks Equity Research
Let's take a sneak peek at a few major Healthcare stocks slated to release their fourth-quarter numbers on Feb 14:
Top Medical Services Stocks To Buy
by Brian Bolan
This highly ranked industry is home to a lot of attractive stocks right now.